Philippe Houyau Selected Research

Alemtuzumab (Campath)

1/2015

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philippe Houyau Research Topics

Disease

1	Neoplasm Metastasis (Metastasis) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2015
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2015

Drug/Important Bio-Agent (IBA)

1	folfirinoxIBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	Alemtuzumab (Campath)FDA Link 01/2015
1	Gemcitabine FDA Link 01/2015

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2022
1	Therapeutics 01/2022